HeartSciences (Heart Test Laboratories, Inc.)

About:

HeartSciences applies AI-based technology to an ECG to expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction.

Website: http://www.heartsciences.com

Twitter/X: HeartSciences

Description:

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.

Total Funding Amount:

$33.2M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Southlake, Texas, United States

Founded Date:

2008-01-01

Contact Email:

info(AT)heartsciences.com

Founders:

Drew Diaz

Number of Employees:

11-50

Last Funding Date:

2024-09-12

IPO Status:

Public

© 2024 MyAiNote.com